

Special Issue

Neuropathology: From Molecular Mechanisms to Therapeutic Solutions

Message from the Guest Editors

In recent years, there has been a dramatic increase in the number of patients with neurological diseases. This has exerted a major societal and financial burden worldwide, and these diseases remain a major cause of disability. Many neurological disorders strike primarily in mid- to late life; their incidence is expected to soar as the population ages. By 2030, as many as one in five Americans will be over the age 65, and more than 12 million Americans will suffer from neurological disorders. Promising studies have been made to understand the molecular mechanisms of disease progression and detailed insights into potential therapeutic solutions. This Special Issue focuses on new and fast-developing knowledge on the disease mechanisms and therapeutic approaches for neurological diseases.

The Special Issue intends to highlight the advances in our understanding of the molecular mechanisms of neurological disorders and potential therapeutic solutions to slow down or prevent the progression of the diseases. With the Special Issue, we hope to provide a comprehensive overview from molecular mechanisms to therapeutic solutions of neurological diseases for the broad readership of the journal.

Guest Editors

Dr. Wenqiang Fan

Department of Neuroscience, UCB Biopharma SPRL, 1420 Braine-l'Alleud, Belgium

Dr. Xingping Qin

Harvard School of Public Health, Harvard University, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (31 July 2023)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/160049

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.